Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Randomized, Single Dose, 5-Period, 5-Treatment Study to Evaluate the Relative Bioavailability and Effect of Food on TAK-831 Tablet Formulations in Healthy Subjects

NCT03706469 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT03706469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Randomized, Single Dose, 5-Period, 5-Treatment Study to Evaluate the Relative Bioavailability and Effect of Food on TAK-831 Tablet Formulations in Healthy Subjects
Lead sponsor
Neurocrine Biosciences
Phase
Phase 1
Overall status
Completed
Start date
October 18, 2018
Completion date
December 22, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers